Tokyo's Astellas Pharma Inc. has completed its $384 million purchase of Marlborough's Ocata Therapeutics.
Astellas completed the purchase of all outstanding stock for Ocata Therapeutics, which researches treatments for eye diseases, through its subsidiary Laurel Acquisition Inc. Laurel was then merged into Ocata on Feb. 10. Neither company has said how the acquisition will impact Ocata's 39 local employees or operations.
The purchase was approved by the boards of directors of Ocata and Astellas. As a result of the merger, Ocata's common stock has ceased to be traded on the NASDAQ Global Market and will no longer be listed.